Stonvex
Stonvex
StonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.45 | $0.45 | +0.40% | 0.0M |
| 05-12 | $0.40 | $0.43 | +6.25% | 2.6M |
| 05-13 | $0.40 | $0.45 | +11.03% | 0.1M |
| 05-14 | $0.44 | $0.45 | +2.03% | 0.2M |
| 05-15 | $0.46 | $0.45 | -3.00% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No SEC filings available for GELS yet.
We expected SEC EDGAR XBRL data here. The issuer may file under a non-standard form, or the latest filing hasn't been parsed yet — try again later or report it via support.
Public market data, filings, and news are still available on this ticker via the other tabs.
No sell-side coverage available for GELS.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for GELS.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.